Sciannamblo, M; et, AL
Reduced bone mineral density and increased bone metabolism in young adult patients with 21-hydroxylase deficiencyJ Clin Endocrinol Metab. Bd. 9. H. 11. 2006 S. 4453-8
Otto, G; Herber, S; Heise, M et al.
Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma.Liver Transpl. Bd. 12. H. 8. 2006 S. 1260-7
Hennes, EM; Czaja, AJ; Pares, A et al.
Simplified Diagnostic Criteria for Autoimmune Hepatitis (Autoimmune Hepatitis Group)Z Gastroenterol. 2006 S. 44 (1)
Dittmar, M; Bischofs, C; Poppe, R et al.
Single radial immune diffusion assay confirms reduced DNase activity in endocrine autoimmunity as measured by ELISAExp Clin Endocr Diab. H. S1. 2006 S. P12
Ide, MF; Dittmar, M; Wurm, M et al.
Specific genotype variations of Interleukin-10.G (IL-10.G) and MHC class I chain-related gene A (MICA) short tandem repeat polymorphisms in thyroid autoimmunityExp Clin Endocr Diab. H. S!. 2006 S. P12
Wehler, T; Wolfert, F; Schimanski, CC et al.
Strong expression of chemokine receptor CXCR4 by pancreatic cancer correlates with advanced disease.Oncol Rep. Bd. 16. H. 6. 2006 S. 1159-64
Kausche, S; Wehler, T; Schnürer, E et al.
Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.Cancer Res. Bd. 66. H. 23. 2006 S. 11447-11454
Fottner, C; Helisch, A; Schreckenberger, M et al.
Superiority of 6-[18F]-Fluorodopamin Positron Emission Tomography (DOPA-PET) versus [123J]-Metaiodobenzylguanidine (MIBG) Scintigraphy in the localization of extraadrenal or multifocal pheochromocytomas and paragangliomoas. 50th Annual Meeting of the German Society of EndocrinologyExp Clin Endocr Diab. Bd. 114. 2006 S. P01-002
Schulze-Bergkamen, H; Fleischer, B; Schuchmann, M et al.
Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction.BMC Cancer. Bd. 6. 2006 S. 232
Fottner, C; Helisch, A; Minnemann, T et al.
Targeted peptide receptor radionuclide for advanced neuroendocrine tumors (NET) with 90 Y-DOTATOC - tumor response and clinical benefit. 50th Annual Meeting of the German Society of EndocrinologyExp Diabesity Res. Bd. 114. 2006 S. P05-069